As one out of only 11 companies, Ascendis is very proud to have signed the Marseille Declaration for Worldwide Implementation of High Standards for Animals Housed and Used Internally and Externally by the Industry for Scientific Purposes. The Declaration outlines requirements on important aspects of housing and care of research animals, continuous education of staff and the need for institutional oversight in relation to animal welfare. Together, signatories of the Marseille Declaration are very pleased that it is working and fostering dialogue between the pharmaceutical industry and CROs, who are working together to consistently prioritize and continuously improve the welfare of all animals used in research. With #AscendisPharma as a new signatory, this coalition to improve animal welfare worldwide is growing. Merck Group, Novo Nordisk, Sanofi, Novartis, LEO Pharma, Lundbeck, BioReliance, EyeCRO, preclinics GmbH, NUVISAN The Science CRO #marseilledeclaration #animalresearch #3rs #animalwelfare #animalcare #biomedicalresearch
Ascendis Pharma
Forskning inden for bioteknologi
Hellerup, Capital Region of Denmark 52.486 følgere
Committed to making a meaningful difference for patients
Om os
Ascendis Pharma is applying our innovative TransCon technology platform to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients’ lives. Guided by our core values of patients, science and passion, we utilize our TransCon technology platform to create new and potentially best-in-class therapies. Ascendis Pharma currently has three independent endocrinology rare disease product candidates in clinical development and we're also advancing programs in Oncology and Ophthalmology. Ascendis Pharma is headquartered in Copenhagen, Denmark, with additional offices in Heidelberg, Munich, and Berlin, Germany, Palo Alto and Redwood City, California, and Princeton, New Jersey.
- Websted
-
http://www.ascendispharma.com
Eksternt link til Ascendis Pharma
- Branche
- Forskning inden for bioteknologi
- Virksomhedsstørrelse
- 501 – 1.000 medarbejdere
- Hovedkvarter
- Hellerup, Capital Region of Denmark
- Type
- Aktieselskab
- Grundlagt
- 2007
- Specialer
- Endocrinology, Oncology, Drug Development, Innovation, Globalization , Ophthalmology og TransCon Technology
Beliggenheder
-
Primær
Tuborg Boulevard 12
Hellerup, Capital Region of Denmark 2900, DK
Medarbejdere hos Ascendis Pharma
Opdateringer
-
#HCPs #AscendisPharma is attending this year’s Turner Syndrome Society of the United States National Turner Syndrome Conference in Orlando. We look forward to engaging with attendees there.
-
-
#HCPs #AscendisPharma is so excited to attend the The MAGIC Foundation's 30th Annual Convention for families affected by growth disorders. Visit our booth to learn more about our work in pediatric #growthhormonedeficiency. #MAGICConference
-
-
Today, #AscendisPharma is acknowledging #ChronicDiseaseDay to shed light on the impact that chronic diseases have on the health and well-being of patients around the world. #hypoparathyroidism #growthhormonedeficiency #achondroplasia
-
-
#AscendisPharma will be at the 2024 Achondroplasia & Skeletal Dysplasia Research Conference, hosted by The Chandler Project, in Baltimore this weekend. We look forward to interacting with attendees and sharing more about our work in #achondroplasia.
-
-
Our U.S. team is attending the 2024 USPHS Scientific & Training Symposium from June 24-27. We look forward to connecting with pharmaceutical industry professionals in Jacksonville. #AscendisPharma
-
-
#HCPs Professor Ravi Savarirayan will give an oral presentation of 1-year physical functioning and well-being data from the Phase 2 ACcomplisH trial in children with #achondroplasia at the 2024 International Conference on Children’s Bone Health. The #AscendisPharma team hopes to see you there on June 24.
-
-
#HCPs #AscendisPharma is heading to Salzburg for the 11th International Conference on Children’s Bone Health. Come visit us at booth 13 to learn more about our work in #achondroplasia.
-
-
#HCPs At this year’s #ENDO2024, #AscendisPharma will share results from the Phase 3 foresiGHt clinical trial in adult #growthhormonedeficiency on June 3.
-
-
We are proud to partner with organizations like the HypoPARAthyroidism Association who strive to make a difference in patients’ lives by driving #hypoPARA community support, education, stories, and resources. #raredisease #hypoparathyroidism
-
Tilsvarende sider
Finansiering
Seneste runde
Post IPO-gæld150.000.000,00 US$
Investorer